This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nucci, M. Articles by Anaissie, E. Search for Related Content PubMed PubMed Citation Articles by Nucci, M. Articles by Anaissie, E.

Fusarium Infections in Immunocompromised Patients

University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil,¹ University of Arkansas for Medical Sciences, Little Rock, Arkansas²

Fusarium species cause a broad spectrum of infections in humans, including superficial, locally invasive, and disseminated infections. The clinical form of fusariosis depends largely on the immune status of the host and the portal of entry, with superficial and localized disease occurring mostly in immunocompetent patients and invasive and disseminated disease affecting immunocompromised patients. Risk factors for severe fusariosis include prolonged neutropenia and T-cell immunodeficiency, especially in hematopoietic stem cell transplant recipients with severe graft-versus-host disease. The most frequent presentation of disseminated fusariosis is a combination of characteristic cutaneous lesions and positive blood cultures, with or without lung or sinus involvement. The prognosis is poor and is determined largely by degree of immunosuppression and extent of infection, with virtually a 100% death rate among persistently neutropenic patients with disseminated disease. These infections may be clinically suspected on the basis of a constellation of clinical and laboratory findings, which should lead to prompt therapy. Treatment options include the lipid formulations of amphotericin B, voriconazole, and posaconazole. Prevention of fusarial infection among high-risk patients should be considered.

This article has been cited by other articles:

• Tortorano, A. M., Prigitano, A., Dho, G., Esposto, M. C., Gianni, C., Grancini, A., Ossi, C., Viviani, M. A. (2008). Species Distribution and In Vitro Antifungal Susceptibility Patterns of 75 Clinical Isolates of Fusarium spp. from Northern Italy. Antimicrob. Agents Chemother. 52: 2683-2685 [Abstract] [Full Text]  
• Azor, M., Gene, J., Cano, J., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Guarro, J. (2008). In Vitro Antifungal Susceptibility and Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob. Agents Chemother. 52: 2228-2231 [Abstract] [Full Text]  
• Ruiz-Cendoya, M., Marine, M., Guarro, J. (2008). Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother 0: dkn215v1-4 [Abstract] [Full Text]